Gilead has lifted the curtain on new Phase 2/3 efficacy data for Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, also known as BIC/FTC/TAF), revealing that the drug demonstrated high efficacy in maintaining virologic suppression in already virologically suppressed adolescents and children aged six years and older living with HIV.
Ook interessant voor je
